Quarterly ResultApr 30, 2026, 04:31 PM
DBVT Q1 Net Loss $(47.6)M; Cash $229M; BLA Filings on Track
AI Summary
DBV Technologies reported a net loss of $(47.6) million for Q1 2026, compared to $(27.1) million in Q1 2025, with net loss per share improving to $(0.11) due to a strengthened equity base. The company held $229 million in cash and cash equivalents as of March 31, 2026, providing funding into Q2 2027. DBV is progressing towards BLA filings for its VIASKIN® Peanut Patch for children aged 4-7 in H1 2026 and toddlers aged 1-3 in H2 2026, and plans to initiate a Phase 2 THRIVE study in infants.
Key Highlights
- Cash and cash equivalents were $229 million as of March 31, 2026, up from $194 million on December 31, 2025.
- Net loss for Q1 2026 was $(47.6) million, compared to $(27.1) million in Q1 2025.
- Net loss per share improved to $(0.11) in Q1 2026 from $(0.26) in Q1 2025.
- R&D expenses increased by $12 million to $(33.4) million in Q1 2026, driven by clinical activities and BLA-readiness.
- SG&A expenses increased by $9 million to $(15.3) million in Q1 2026, reflecting U.S. commercial infrastructure build-out.
- Net cash used for operating activities was $(49) million in Q1 2026, up from $(20) million in Q1 2025.
- Net cash provided by financing activities totaled $89 million in Q1 2026 from warrant exercises.
- Cash runway extends into the second quarter of 2027.